Macitentan tadalafil fixed dose combination (FDC) in patients with pulmonary arterial hypertension (PAH): A subgroup analysis from A DUE - Milan 2023

From diagnosis to therapy in pulmonary arterial hypertension

Chair(s): Horst Olschewski, Etienne-Marie Jutant

Session type: Poster session

Macitentan tadalafil fixed dose combination (FDC) in patients with pulmonary arterial hypertension (PAH): A subgroup analysis from A DUE

Pavel Jansa

EVENTS HOME

Poster
Abstract

Previous presentation

Next presentation

Session content

The UPHILL study: a nutrition and lifestyle intervention to improve quality of life for patients with pulmonary arterial hypertension

Chermaine Kwant

Poster

Abstract

Treprostinil transition from subcutaneous to intravenous in pediatric patients with Pulmonary Hypertension undergoing a risky procedure.

Ana Diez Izquierdo

Poster

Abstract

Initial dual oral combination therapy in patient with pulmonary arterial hypertension and cardiovascular comorbidities

Athenais Boucly

Poster

Abstract

Rodatristat ethyl: characterization of reductions in peripheral serotonin supportive of ELEVATE 2, a Phase IIb clinical study for pulmonary arterial hypertension

Courtney Mckernan

Abstract

Impact of the new definition of precapillary pulmonary hypertension on the prevalence of portopulmonary hypertension in patients referred for liver transplantation

Helene Pringuez

Poster

Abstract

End-of-life healthcare resource utilization and costs in patients with PAH: a real-world analysis

Dominik Lautsch

Poster

Abstract

Management of acute decompensated pulmonary arterial hypertension: results of the ERS Clinical Research Collaboration PHAROS survey

Laurent Savale

Poster

Abstract

Methamphetamine and idiopathic PAH: Similar treatment, similar outcomes

Cole Uhland

Poster

Abstract

Living with pulmonary hypertension a cross-sectional survey of UK patients

Iain Armstrong

Abstract

Treatment-associated changes in cardiopulmonary exercise test variables: upfront combination vs monotherapy in pulmonary arterial hypertension

Andrea Baccelli

Poster

Abstract

Use of Long-term Oxygen Therapy in Patients With Pulmonary Hypertension in Spain

Rodrigo Torres Castro

Poster

Abstract

A UK national patient survey of attitudes towards aspects of novel clinical trial design in pulmonary hypertension

Joseph Newman

Poster

Abstract

As time goes by... 2022 versus 2011 ERS-CRC PHAROS survey on managing pulmonary arterial hypertension (PAH) in European expert centres

Adam Torbicki

Poster

Abstract

The impact of comorbidities on inhaled treprostinil treatment in patients with pulmonary arterial hypertension

Vallerie Mclaughlin

Poster

Abstract

Pulmonary arterial hypertension with comorbidities does dual therapy have a role?

Julia Thomas

Poster

Abstract

A real-word evidence study of PH-LD, PH-ILD and PAH in France, Germany, and the UK

John Wort

Poster

Abstract

Macitentan tadalafil fixed dose combination (FDC) in patients with pulmonary arterial hypertension (PAH): A subgroup analysis from A DUE

Pavel Jansa

Poster

Abstract

Diagnosing pulmonary arterial hypertension in the Real World

Rogier Klok

Poster

Abstract

A randomized study to evaluate the effects of single-dose MK-5475 co-administered with sildenafil on systemic hemodynamics

Mahesh J. Patel

Poster

Abstract

Rodatristat ethyl: peripheral serotonin targeting with low risk for impacting mood supportive of ELEVATE 2, a Phase IIb clinical study for pulmonary arterial hypertension

Michelle Palacios

Abstract

CDN Connection Issue

The ERS International Congress 2023, Milan

#{title}